1. Home
  2. ACDC vs PHVS Comparison

ACDC vs PHVS Comparison

Compare ACDC & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ProFrac Holding Corp.

ACDC

ProFrac Holding Corp.

HOLD

Current Price

$3.81

Market Cap

703.6M

Sector

Energy

ML Signal

HOLD

Logo Pharvaris N.V.

PHVS

Pharvaris N.V.

HOLD

Current Price

$25.54

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACDC
PHVS
Founded
2014
2015
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Oilfield Services/Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
703.6M
1.7B
IPO Year
2022
2021

Fundamental Metrics

Financial Performance
Metric
ACDC
PHVS
Price
$3.81
$25.54
Analyst Decision
Hold
Buy
Analyst Count
3
9
Target Price
$5.83
$39.44
AVG Volume (30 Days)
1.3M
526.6K
Earning Date
11-10-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,960,000,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.08
$11.51
52 Week High
$10.70
$29.80

Technical Indicators

Market Signals
Indicator
ACDC
PHVS
Relative Strength Index (RSI) 44.23 51.80
Support Level $3.78 $23.79
Resistance Level $4.01 $27.45
Average True Range (ATR) 0.24 1.57
MACD -0.03 0.00
Stochastic Oscillator 9.15 34.75

Price Performance

Historical Comparison
ACDC
PHVS

About ACDC ProFrac Holding Corp.

ProFrac Holding Corp is engaged in providing hydraulic fracturing, completion services, and other complementary products and services to upstream oil and gas companies engaged in the exploration and production of North American unconventional oil and natural gas resources. The company operates in three segments: Stimulation Services, Proppant Production, and Manufacturing. Stimulation services, which generate the majority of the revenue for the company operate a fleet of mobile hydraulic fracturing units and other auxiliary equipment that generates revenue by providing stimulation services.

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.

Share on Social Networks: